Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

Samsung Medical Center

Status: Enrolling

Conditions: Haploidentical Hematopoietic Stem Cell Transplantation

Treatments: Drug: ATG-LDPTCy

Study type: Observational

Funder types: Other

Identifiers

NCT06041893

SMC 2023-03-094-002

Details and patient eligibility

About

Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.

Full description

Hematopoietic stem cell transplantation from a haploidentical donor (haplo-HCT) are increasingly used in patients lacking a matched donor, but the optimal strategy needs to be defined. This study aims to investigate the outcome of haplo-HCT with early antithymocyte globulin and low dose posttransplant cyclophosphamide (ATG/LD-PTCy) in a single center.

Enrollment: 20 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.

Exclusion criteria

• A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.

Trial design

20 participants in 1 patient group

ATG/LD-PTCy group

Description:

Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center

Treatment:

Drug: ATG-LDPTCy